AbbVie Stock Rises After Earnings Beat

Analyst revises AbbVie stock price target on drug-sale estimates

"We are demonstrating a rapid return to revenue growth with operational sales up nearly 4% through the first half of this year, including robust ...

AbbVie stock up 2% after earnings beat and raised outlook

Shares of AbbVie Inc. rose 2% in premarket trade Thursday after the drugmaker reported first-quarter earnings and revenue that beat Wall ...

GREAT Time To Buy BARGAIN AbbVie After Strong Earnings?!

Stock Valuation Model: https://www.buymeacoffee.com/dividendtalks/extras Feel free to buy me a coffee: ...

AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs

Shares of AbbVie were up 0.8% in pre-market trading on Feb 2, likely due to the encouraging guidance. In the past year, the stock has gained ...

AbbVie (ABBV) Earnings Date and Reports 2024 - MarketBeat

AbbVie released Q3 2024 earnings on October 30, 2024, reporting an EPS of $3.00, which beat analysts' consensus estimates of $2.92 by $0.08.

AbbVie stock up 2% after earnings beat - MarketWatch

AbbVie stock up 2% after earnings beat ... Shares of AbbVie Inc. rose 2% in premarket trade Friday after the drugmaker reported profit and revenue ...

AbbVie: 3 Positives From The Earnings Report (NYSE:ABBV)

But the release of its third quarter (Q3 2024) results shows investors are happy with the numbers, rewarding the stock with over a 6% rise in ...

AbbVie earnings beat by $0.08, revenue topped estimates

AbbVie's stock price closed at $189.45. It is up 0.08% in the last 3 months and up 34.19% in the last 12 months. AbbVie saw 8 positive EPS ...

AbbVie Inc. CDR (ABBV) Stock Price Today | The Dividend Tracker

AbbVie stock rose after the drugmaker posted quarterly earnings that surpassed analysts' expectations. The company reported third-quarter adjusted earnings of ...

ABBV.N - | Stock Price & Latest News - Reuters

AbbVie Inc ; Previous Close: 174.43 ; Open: 176.01 ; Volume: 2,703,364.00 ; 3 Month Average Trading Volume: 105.64 ; Shares Out (Mil): 1,767.14.

Buy 3 Retail Giants Poised To Beat On Earnings This Month

AbbVie stock is up 13.2% year to date, compared to the S&P 500 Index's ($SPX) 25.6% gain. The stock is also currently cheap, and trading lower ...

AbbVie (ABBV) Earnings Dates & Reports - TipRanks.com

AbbVie (ABBV) will release its next earnings report on Jan 28, 2025. In the last quarter AbbVie reported $2.92 EPS in relation to $3 expected by the market.

AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? - Zacks

... stock after the recent price dip. ... Past performance is no guarantee of future results. Up Next. Westport Q3 Earnings Beat Expectations, ...

AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential

The recent price pullback didn't get very deep and set the market up to fire a continuation signal with a $35 or 20% upside potential. Price ...

ABBV - Abbvie Inc Stock Price and Quote - FINVIZ.com

AbbVie Stock Rises After Earnings Beat, Dividend Hike. (Barrons.com). 08:50AM · AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates. (Zacks). 08:07AM.

ABBV: AbbVie Inc - Stock Price, Quote and News - CNBC

AbbVie Inc ABBV:NYSE ; after hours icon After Hours: Last | 4:55 PM EST. 170.35UNCH (UNCH) ; Volume. 493,811.

Abbvie Inc (Abbv) Stock, Share Price, News & Forecast

... Beat -- IBD. DJ. Read. 30 Oct 2024, 12:34 UTC. Earnings. AbbVie Stock Rises After Earnings Beat, Dividend Hike -- Barrons.com. DJ. Read. 30 Oct ...

ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024

Related Stocks · AbbVie reported earnings per share of $2.31. This was above the analyst estimate for EPS of $2.23. · The company reported revenue ...

ABBV Stock Quote Price and Forecast - CNN

View AbbVie, Inc. ABBV stock quote prices, financial information, real ... since last year and increased 13.99% since last quarter. Key terms. Total ...

What's behind AbbVie's Q3 revenue beat? - Seeking Alpha

AbbVie (ABBV) stock hits all-time high after beating Q3 earnings expectations with newer immunology drugs outperforming Humira.